Clinical Lymphoma Myeloma and Leukemia This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
Monoclonal proteins are common, with a prevalence in the United States around 5% and the incidence increases with age. Although most patients are asymptomatic, the vast majority of cases are caused by a clonal plasma cell disorder. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are asymptomatic precursor conditions with variable risk of progression to multiple myeloma (MM). In recent years, significant progress has been made to better understand the factors that lead to the development of symptoms and progression to myeloma. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 16, 2024 Category: Hematology Authors: Timothy Schmidt, Zhubin Gahvari, Natalie S. Callander Tags: Review Article Source Type: research

BCMA directed Bispecific Antibody induced tumour flare in Multiple Myeloma
Bispecific antibodies have emerged as highly effective treatments for multiple myeloma patients even in late relapse when all available novel agents have been exhausted. However, they cause some adverse events of special interest (AESI) that treating physicians need to be aware of. AESIs like CRS and ICANS are reasonably wellcaptured and reported in most early phase and pivotal studies and their management strategies have been well discussed, debated, and published. However, tumour flare reactions caused by BsAb induced T-cell activation and associated inflammatory reaction have hardly been reported in the pivotal trials o...
Source: Clinical Lymphoma, Myeloma and Leukemia - March 16, 2024 Category: Hematology Authors: Dr. Chandramouli Nagarajan, Dr. Thomas G Martin Tags: Letter to the Editor Source Type: research

SOHO State of the Art Updates and Next Questions | Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
Monoclonal proteins are common, with a prevalence in the United States around 5% and the incidence increases with age. Although most patients are asymptomatic, the vast majority of cases are caused by a clonal plasma cell disorder. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are asymptomatic precursor conditions with variable risk of progression to multiple myeloma (MM). In recent years, significant progress has been made to better understand the factors that lead to the development of symptoms and progression to myeloma. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 16, 2024 Category: Hematology Authors: Timothy Schmidt, Zhubin Gahvari, Natalie S. Callander Source Type: research

Average Temperature as a Marker of Lymphoma-Associated HLH
Peak temperature, and 12-hour mean temperature were analysed in lymphoma patients presenting with a significantly raised serum ferritin. 12 (out of 23) patients were found to have hemophagocytic lymphohistiocytosis (HLH). 12-hour temperature proved a better predictor of HLH than peak temperature in this cohort, which has highlighted the need for further research into this simple clinical parameter. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 10, 2024 Category: Hematology Authors: Cameron Clark, Jack Goddard, Rachel Tattersall, Nick Morley Tags: Original Study Source Type: research

Average temperature as a marker of lymphoma-associated HLH.
Haemophagocytic Lymphohistiocytosis (HLH) is a rare and poorly recognised systemic, hyperinflammatory clinical syndrome associated with a high mortality in those affected.1 In its primary form, HLH is characterised by the presence of genetic abnormalities and typically affects children. Secondary HLH is an altogether more heterogenous condition associated with autoimmune disease, infection and malignancy.2 The pathophysiology of secondary HLH represents immune dysfunction and dysregulation resulting in a continuous cycle of hyperinflammation causing widespread tissue injury. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 10, 2024 Category: Hematology Authors: Cameron Clark, Jack Goddard, Rachel Tattersall, Nick Morley Tags: Original Study Source Type: research

Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes
Myelofibrosis (MF) is a clonal disorder of hematopoiesis and the most aggressive subtype among classical BCR::ABL1 negative myeloproliferative neoplasms (MPN). Approximately 90% of patients harbor a mutation affecting JAK2, MPL, or CALR signaling which results in constitutive activation of the JAK/STAT pathway and culminates in proliferative and dysfunctional blood cell production, extramedullary hematopoiesis, and constitutional symptoms. Conversely, 5-10% of patients are deemed to be “triple-negative” (TN), a designation associated with poor prognosis (1). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 10, 2024 Category: Hematology Authors: Luis E. Aguirre, Akriti Jain, Somedeb Ball, Najla Al Ali, Virginia O. Volpe, Sara Tinsley-Vance, David Sallman, Kendra Sweet, Jeffrey Lancet, Eric Padron, Seongseok Yun, Andrew Kuykendall, Rami Komrokji Tags: Original Study Source Type: research

Prevalence and consequences of a delayed diagnosis in multiple myeloma: A single institution experience
Multiple myeloma (MM) is a disease with unspecific initial symptoms which may lead into a delay in the diagnosis, seemingly increasing the risk of complications and in turn reducing the overall survival (OS). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 9, 2024 Category: Hematology Authors: Paola Negrete-Rodr íguez, Moisés Manuel Gallardo-Pérez, Olivia Lira-Lara, Miranda Melgar-de-la-Paz, Luis Enrique Hamilton-Avilés, Guillermo Ocaña-Ramm, Max Robles-Nasta, Daniela Sánchez-Bonilla, Juan Carlos Olivares-Gasca, María-Victoria Mateos, Gu Tags: Original Study Source Type: research

SOHO State of the Art Updates and Next Questions | Early Intervention in Myelofibrosis: Where are we and Does It Matter?
Historically, therapeutic clinical trials in myelofibrosis have predominantly focused on targeting patients with higher-risk disease who are at risk of increased morbidity and mortality. The endpoints have been designed to target regularly measured disease parameters that are of immediate pertinence to patient's welfare including splenic volume reduction, and symptom reduction. These efforts have resulted in meaningful and measurable improvements in disease parameters in these high-risk study populations and multiple FDA approved agents. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 5, 2024 Category: Hematology Authors: Abdulraheem Yacoub, Nicole Twardowski, Alec Britt, Nour Shraim Tags: Review Article Source Type: research

SOHO State of the Art Updates and Next Questions | Novel Agents and the Diminishing Role of Allogeneic Stem Cell Transplant in B-Acute Lymphoblastic Leukemia
Outcomes of patients with B-acute lymphoblastic leukemia (B-ALL) have improved remarkably in the past decade. This has largely been due to the development and introduction of novel immunotherapies such as blinatumomab, inotuzumab ozogamicin, chimeric antigen receptor T (CAR-T) cells, highly potent tyrosine kinase inhibitors, and improved risk stratification, including better understanding of high risk genomic subgroups and better methods of measurable residual disease (MRD) detection. Historically, allogeneic stem cell transplant (allo-SCT) has been the consolidative treatment of choice in first complete remission for fit ...
Source: Clinical Lymphoma, Myeloma and Leukemia - March 5, 2024 Category: Hematology Authors: Wei-Ying JEN, Elias JABBOUR, Hagop M. KANTARJIAN, Nicholas J. SHORT Source Type: research

Using Proton Pump Inhibitors is not Associated with Adverse Outcomes in Patients with Chronic Myeloid Leukemia Treated with Dasatinib
Treatment with the BCR::ABL1 tyrosine kinase inhibitors (TKIs) has markedly improved the outcome of patients with chronic myeloid leukemia (CML). These oral therapies are convenient but raise the concern of potential gastrointestinal malabsorption due to drug-drug interactions. This could compromise the treatment efficacy and result in adverse events (e.g., increasing the concentration of a drug beyond the therapeutic index).1 An important factor influencing TKI absorption is the change in gastric pH. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 29, 2024 Category: Hematology Authors: Fadi G. Haddad, Cedric Nasnas, Koji Sasaki, Shilpa Paul, Ghayas C. Issa, Caitlin Rausch, Elias Jabbour, Hagop Kantarjian Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 27, 2024 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 27, 2024 Category: Hematology Source Type: research

Financial toxicity, time toxicity, and quality of life in multiple myeloma
Patients with multiple myeloma (MM) may be on therapy for years, which can lead to financial toxicity (FinTox) or time toxicity (TimeTox). The prevalence, predictors, and quality of life (QOL) impacts of FinTox and TimeTox during different phases of MM treatment have not been characterized. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 22, 2024 Category: Hematology Authors: Rahul Banerjee, Andrew J. Cowan, Marivel Ortega, Constance Missimer, Paul A. Carpenter, Masumi Ueda Oshima, Rachel B. Salit, Phuong T. Vo, Catherine J. Lee, Rohtesh S. Mehta, Nicole M. Kuderer, Veena Shankaran, Stephanie J. Lee, Christopher T. Su Source Type: research

PORT: A Randomized, Cross-over, Phase 2 Study of Melflufen Peripheral versus Central Intravenous Administration in Patients with Relapsed/Refractory Multiple Myeloma
Although recent therapeutic advances have significantly improved survival among patients with multiple myeloma,1 it is still considered to be an incurable disease for the majority of patients. With current therapeutic practice with triplet or quadruplet therapies recommended both at initial treatment and in later lines,2,3 patients at second or later relapses are being increasingly refractory to multiple classes of agents.4 Additionally, outcomes for patients with triple-refractory disease remain poor. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 22, 2024 Category: Hematology Authors: Ludek Pour, Ilina Micheva, Ganna Usenko, Gabor Mikala, Tamas Masszi, Kameliya Simeonova, Marcus Thuresson, Gunilla Huledal, Stefan Norin, Nicolaas A. Bakker, Jiri Minarik Tags: Original Study Source Type: research

Dampening Logistics Creating Inequitable Access: A Major Threat Despite Advancements
We read with great interest the recent publication by Shahzad et al. titled “Geographic and Racial Disparities in Chimeric Antigen Receptor–T Cells and Bi-specific Antibodies Trials Access for Diffuse Large B-Cell Lymphoma” which is a report on the distribution across the US of chimeric antigen receptor T cell (CART) and bispecific therapies.1 Shahzad et al. demonstra ted that the 126 studies were distributed over 31 states, however, there is considerable variation by region in the availability of the trial. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 21, 2024 Category: Hematology Authors: Fathima Shehnaz Ayoobkhan, Al- Ola Abdallah, Faiz Anwer, Nausheen Ahmed Tags: Commentary Source Type: research